BiotechTube
PulseSight Therapeutics

PulseSight Therapeutics

Paris, France· Est.
pulsesight.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.8M

Overview

PulseSight Therapeutics is a Paris-based, clinical-stage biotechnology company pioneering a disruptive, non-viral gene therapy platform for ophthalmology. The company's core technology involves a proprietary electro-transfection delivery system that enables sustained expression of therapeutic proteins from plasmids administered into the ciliary muscle. With two lead programs in advanced Phase 1/2 development for dry and wet AMD, PulseSight is targeting a massive global market with a potential paradigm shift in treatment, moving from frequent injections to a one-time, minimally invasive gene therapy. The company is led by an experienced team and backed by leading international life science investors.

OphthalmologyRetinal Diseases

Technology Platform

Proprietary non-viral gene therapy platform using plasmid DNA and an electro-transfection delivery system administered into the ciliary muscle for sustained therapeutic protein expression.

Funding History

1
Total raised:$2.8M
Seed$2.8M

Opportunities

The global AMD market is massive and underserved, especially for dry AMD/GA where treatment options are limited.
PulseSight's one-time, minimally invasive gene therapy could disrupt the standard of care of frequent injections, offering superior compliance and reduced burden.
Success could also enable platform expansion into other retinal diseases.

Risk Factors

Clinical failure of lead candidates in ongoing trials is the primary risk.
The novel electro-transfection platform must prove safe and effective against established standards.
The company operates in a highly competitive AMD landscape against large pharma and will require significant additional capital to reach commercialization.

Competitive Landscape

PulseSight competes in the crowded and rapidly evolving AMD therapeutic space. Competitors include large pharma (Roche/Genentech, Regeneron, Novartis, Bayer) with anti-VEGF biologics and newer drugs for GA, as well as other biotechs developing gene therapies, retinal implants, and oral therapies. Differentiation hinges on its non-viral delivery approach's safety and durability profile.

More companies in CRISPR / Gene Editing →More companies in France →